Advertisement

Allergic and immunologic disorders of the eye. Part II: Ocular allergy

      Abstract

      Allergy affects more than 15% of the world population, and some studies have shown that up 30% of the US population has some form of allergy. Most of these patients have various target organs for their allergies, and most have ocular involvement. The ocular component may be the most prominent and sometimes disabling feature of their allergy. Some are affected for only a few weeks to months, whereas others have symptoms that last throughout the year. The seasonal forms may present to clinical allergists, whereas the more chronic forms may present to ophthalmologists. Thus, in the second of this 2-part review series (Part I: Ocular Immunology appeared in the November issue of the Journal), an overview is provided of the spectrum of ocular allergy that ranges from acute seasonal allergic conjunctivitis to chronic variants of atopic keratoconjunctivitis. With a better understanding of the immunologic mechanisms, we now can develop better treatment approaches and design further research in intervention of allergic eye diseases. (J Allergy Clin Immunol 2000;106:1019-32.)

      Keywords

      Abbreviations:

      AKC: (Atopic keratoconjunctivitis), ECP: (Eosinophil cationic protein), GPC: (Giant papillary conjunctivitis.), ICAM: (Intracellular adhesion molecule), LT: (Leukotriene), MBP: (Major basic protein), PAC: (Perennial allergic conjunctivitis), SAC: (Seasonal allergic conjunctivitis), VKC: (Vernal keratoconjunctivitis)
      To read this article in full you will need to make a payment

      References

        • Nathan RA
        • Meltzer EO
        • Selner JC
        • Storms W
        Prevalence of allergic rhinitis in the United States.
        J Allergy Clin Immunol. 1997; 99: S808-S814
        • Dykewicz MS
        • Fineman S
        Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis.
        Ann Allergy Asthma Immunol. 1998; 81: 463-468
        • Juniper EF
        • Guyatt GH
        • Dolovich J
        Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials.
        J Allergy Clin Immunol. 1994; 93: 413-421
        • Ray NF
        • Baraniuk JN
        • Thamer M
        • et al.
        Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses.
        J Allergy Clin Immunol. 1999; 103: 401-407
        • Friedlaender MH
        Current concepts in ocular allergy.
        Ann Allergy. 1991; 67: 5-13
        • Marrache F
        • Brunet D
        • Frandeboeuf J
        • et al.
        The role of ocular manifestations in childhood allergy syndromes.
        Rev Fr Allergol Immunol Clin. 1978; 18: 151-155
        • Weeks ER
        Epidemiology of hay fever and perennial allergic rhinitis.
        Monogr Allergy. 1987; 21: 1-20
        • Davies RJ
        • Rusznak C
        • Devalia JL.
        Why is allergy increasing?—environmental factors.
        Clin Exp Allergy. 1998; 28: 8-14
        • Rachelefsky GS
        National guidelines needed to manage rhinitis and prevent complications.
        Ann Allergy Asthma Immunol. 1999; 82: 296-305
        • Nimmagadda SR
        • Evans 3rd, R
        Allergy: etiology and epidemiology.
        Pediatr Rev. 1999; 20: 111-115
        • Hjern A
        • Haglund B
        • Hedlin G
        Ethnicity, childhood environment and atopic disorder.
        Clin Exp Allergy. 2000; 30: 521-528
        • Ciprandi G
        • Buscaglia S
        • Pesce GP
        • Bagnasco M
        • Canonica GW
        Ocular challenge and hyperresponsiveness to histamine in patients with allergic conjunctivitis.
        J Allergy Clin Immunol. 1993; 91: 1227-1230
        • Dart JK
        • Buckley RJ
        • Monnickendan M
        • Prasad J
        Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis.
        Trans Ophthalmol Soc UK. 1986; 105: 513-520
        • Goldberg A
        • Confino-Cohen R
        • Waisel Y
        Allergic responses to pollen of ornamental plants: high incidence in the general atopic population and especially among flower growers.
        J Allergy Clin Immunol. 1998; 102: 210-214
        • Bourcier T
        • Moldovan M
        • Goldschild M
        • Becquet F
        • Brignole F
        • Goguel A
        • et al.
        Value of lacrimal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis.
        J Fr Ophtalmol. 1998; 21: 209-213
        • Trocme SD
        • Bonini S
        • Barney NP
        • Bloch KJ
        • Allansmith MR
        Late-phase reaction in topically induced ocular anaphylaxis in the rat.
        Curr Eye Res. 1988; 7: 437-443
        • Bonini S
        • Bonini S
        • Vecchione A
        • Naim DM
        • Allansmith MR
        • Balsano F
        Inflammatory changes in the conjunctival scrapings after allergen provocation in humans.
        J Allergy Clin Immunol. 1988; 82: 462-469
        • Bonini S
        • Bonini S
        • Bucci MG
        Allergen dose response and late symptoms in a human model of ocular allergy.
        J Allergy Clin Immunol. 1990; 86: 869-876
        • Leonardi A
        • Briggs RM
        • Bloch KJ
        • Allansmith MR
        Histology of ocular late-phase reaction in guinea pigs passively sensitized with IgG1 antibody.
        Ophthalmic Res. 1990; 22: 209-219
        • Leonardi A
        • Briggs RM
        • Bloch KJ
        • Allansmith MR
        Clinical patterns of ocular anaphylaxis in guinea pigs passively sensitized with IgG1 antibody.
        Ophthalmic Res. 1990; 22: 95-105
        • Bonini S
        • Centofanti M
        • Schiavone M
        • Bonini S
        Passive transfer of the ocular late phase reaction.
        Ocul Immunol Inflamm. 1993; 1: 323-325
        • George MA
        • Smith LM
        • Berdy GJ
        • et al.
        Platelet activating factor induced inflammation following topical ocular challenge.
        Invest Ophthalmol Vis Sci. 1990; 31: 63
        • Ciprandi G
        • Buscaglia G
        • Pesce GP
        • Bagnasco M
        • Canonica GW
        Ocular challenge and hyper-responsiveness to histamine in patients with allergic conjunctivitis.
        J Allergy Clin Immunol. 1993; 91: 1227-1230
        • Magone MT
        • Whitcup SM
        • Fukushima A
        • Chan CC
        • Silver PB
        • Rizzo LV
        The role of IL-12 in the induction of late-phase cellular infiltration in a murine model of allergic conjunctivitis.
        J Allergy Clin Immunol. 2000; 105: 299-308
        • Zubler P
        • Pecoud A
        Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens.
        J Allergy Clin Immunol. 1988; 82: 590-594
        • Tuft SJ
        • Kemeny EM
        • Dart JKG
        • et al.
        Clinical features of atopic keratoconjunctivitis.
        Ophthalmology. 1991; 98: 150-158
        • Garrity JA
        • Liesegang TJ
        Ocular complications of atopic dermatitis.
        Can J Ophthalmol. 1984; 19: 21-24
        • Karel I
        • Myska V
        • Kvicalova E
        Ophthalmological changes in atopic dermatitis.
        Acta Dermatol Venerol. 1965; 45: 381-386
        • Schudel P
        • Wuthrich B
        Klinische verlaufsbeobachtungen bei neurodermatitis atopic dem kleinkindersalter, Eine katamnestische untersuchung anhand von 121 fallen.
        Z Hautkr. 1985; 60: 479-486
        • Oshinskie L
        • Haine C
        Atopic dermatitis and its ophthalmic complications.
        J Am Optom Assoc. 1982; 53: 889
        • Rich LF
        • Hanifin JM
        Ocular complications of atopic dermatitis and other eczemas.
        Int Ophthalmol Clin. 1985; 25: 61-76
        • Easty DL
        • Entwistle C
        • Fund A
        • Witcher J
        Herpes simplex keratitis and keratoconus in the atopic patient. A clinical and immunological study.
        Trans Ophthalmol Soc UK. 1975; 95: 267-276
        • Dogru M
        • Nakagawa N
        • Tetsumoto K
        • Katakami C
        • Yamamoto M
        Ocular surface disease in atopic dermatitis.
        Jpn J Ophthalmol. 1999; 43: 53-57
        • Foster CS
        • Calonge M
        Atopic keratoconjunctivitis.
        Ophthalmology. 1990; 97: 992-1000
        • Beetham WP
        Atopic cataracts.
        Arch Ophthalmol. 1940; 24: 21-37
        • Copeman PWM
        Eczema and keratoconus.
        BMJ. 1965; 2: 977-979
        • Jacq PL
        • Sale Y
        • Cochener B
        • Lozach P
        • Colin J
        Keratoconus changes in corneal topography and allergy. Study of 3 groups of patients.
        J Fr Ophtalmol. 1997; 20: 97-102
        • Brunsting LA
        • Reed WB
        • Bair HL
        Occurrence of cataracts and keratoconus with atopic dermatitis.
        Arch Dermatol. 1955; 72: 237-241
        • Kornerup T
        • Lodin A.
        Ocular changes in 100 cases of Besnier’s prurigo (atopic dermatitis).
        Acta Ophthalmol. 1959; 37: 508-521
        • Uehara M
        • Amemiya T
        • Arai M
        Atopic cataracts in a Japanese population. With special reference to factors possibly relevant to cataract formation.
        Dermatologica. 1985; 170: 180-184
        • Amemiya T
        • Matsuda H
        • Uehara M
        Ocular findings in atopic dermatitis with special reference to the clinical features of the atopic cataract.
        Ophthalmologica. 1980; 180: 129-132
        • Uchio E
        • Miyakawa K
        • Ikezawa Z
        • Ohno S
        Systemic and local immunological features of atopic dermatitis patients with ocular complications.
        Br J Ophthalmol. 1998; 82: 82-87
        • Montab PG
        • van Hage-Hamsten M
        Eosinophil cationic protein in tears in allergic conjunctivitis.
        Br J Ophthalmol. 1996; 80: 556-560
        • Hogan MJ
        Atopic keratoconjunctivitis.
        Am J Ophthalmol. 1953; 36: 937-947
        • Sasabe T
        • Suwa Y
        • Kawamura T
        • Aoki T
        Cataracts occur in patients with atopic dermatitis when the serum IgE increases.
        Nippon Ganka Gakkai Zasshi. 1997; 101: 389-392
        • Taniguchi H
        • Ohki O
        • Yokozeki H
        • Katayama I
        • Tanaka A
        • Kiyosawa M
        • et al.
        Cataract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid.
        J Dermatol. 1999; 26: 658-665
        • Coles RS
        • Laval J
        Retinal detachments occurring in cataract associated with neurodermatitis.
        Arch Ophthalmol. 1952; 48: 30-39
        • Hurlbut WB
        • Domonkos AN
        Cataract and retinal detachment associated with atopic dermatitis.
        Arch Ophthalmol. 1954; 52: 852-857
        • Ingram RM
        Retinal detachment associated with atopic dermatitis and cataracts.
        Arch Ophthalmol. 1965; 49: 96-97
        • Tuft SJ
        • Ramakrishnan M
        • Seal DV
        • Kemeny M
        • Buckley RJ.
        Role of Staphylococcus aureus in chronic allergic conjunctivitis.
        Ophthalmology. 1992; 99: 180-184
        • Hogan MJ
        Atopic keratoconjunctivitis.
        Trans Am Ophthalmol Soc. 1952; 50: 265-281
        • Avunduk AM
        • Avunduk MC
        • Dayanir V
        • Tekelioglu Y
        Further studies on the immunopathology of atopic keratoconjunctivitis using flow cytometry.
        Exp Eye Res. 1997; 65: 803-808
        • Metz DP
        • Hingorani M
        • Calder VL
        • Buckley RJ
        • Lightman SL
        T-cell cytokines in chronic allergic disease.
        J Allergy Clin Immunol. 1997; 100: 817-824
        • Uchio E
        • Ono SY
        • Ikezawa Z
        • Ohno S
        Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis.
        Clin Exp Allergy. 2000; 30: 103-109
        • Yoshida A
        • Imayama S
        • Sugai S
        • Kawano Y
        • Ishibashi T
        Increased number of IgE positive Langerhans cells in the conjunctiva of patients with atopic dermatitis.
        Br J Ophthalmol. 1997; 81: 402-406
        • Toshitani A
        • Imayama S
        • Shimozono Y
        • Yoshinaga T
        • Furue M
        • Hori Y
        Reduced amount of secretory component of IgA secretion in tears of patients with atopic dermatitis.
        J Dermatol Sci. 1999; 19: 134-138
        • Yokoi K
        • Yokoi N
        • Kinoshita S
        Impairment of ocular surface epithelium barrier function in patients with atopic dermatitis.
        Br J Ophthalmol. 1998; 82: 797-800
        • Foster CS
        • Rice BA
        • Dutt JE
        Immunopathology of atopic keratoconjunctivitis.
        Ophthalmology. 1991; 98: 1190-1196
        • Montan PG
        • Ekstrom K
        • Hedlin G
        • van Hage-Hamsten M
        • Hjern A
        • Herrmann B.
        Vernal keratoconjunctivitis in a Stockholm ophthalmic centre—epidemiological, functional, and immunologic investigations.
        Acta Ophthalmol Scand. 1999; 77: 559-563
        • Tabbara KF
        Ocular complications of vernal keratoconjunctivitis.
        Can J Ophthalmol. 1999; 34: 88-92
        • Irani AA
        • Butrus SI
        • Tabbara KF
        • Schwartz LB
        Human conjunctival mast cells: distribution of MCT and MCTc in vernal conjunctivitis and giant papillary conjunctivitis.
        J Allergy Clin Immunol. 1990; 86: 34-40
        • Romagnani S
        • Maggi E
        • Parronchi P
        • Maccia D
        • Piccinni MP
        • Rica M
        Increased numbers of TH2 like CD4+ T cells in target organs and in the allergen specific repertoire of allergic patients.
        Int Arch Allergy Appl Immunol. 1991; 94: 133-136
        • Maggi E
        • Biswas P
        • DelPrete G
        • et al.
        Accumulation of TH-2 like helper T cells in the conjunctiva of patients with vernal conjunctivitis.
        J Immunol. 1991; 146: 1169-1174
        • Uchio E
        • Ono S
        • Ikezawa Z
        • Ohno S
        Serum levels of soluble intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and interleukin-2 receptor in patients with vernal keratoconjunctivitis and allergic conjunctivitis.
        Allergy. 1999; 54: 135-141
        • Abelson MB
        • Baird RS.
        • Allansmith MR
        Tear histamine levels in vernal conjunctivitis and other ocular inflammations.
        Ophthalmology. 1980; 87: 812-814
        • Secchi A
        • Leonardi A
        • Abelson M
        The role of eosinophil cationic protein (ECP) and histamine in vernal keratoconjunctivitis.
        Ocul Immunol Inflamm. 1995; 3: 23-28
        • Leonardi A
        • Borghesan F
        • Faggian D
        • Secchi A
        • Plebani M
        Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis.
        Allergy. 1995; 50: 610-613
        • Saiga T
        • Ueno N
        • Shimizu Y
        Deposition of eosinophil cationic protein in conjunctival tissues and tears in vernal keratoconjunctivitis.
        Invest Ophthalmol Vis Sci. 1991; 32 ([abstract]) (poster): 682
        • Montab PG
        • van Hage-Hamsten M
        Eosinophil cationic protein in tears in allergic conjunctivitis.
        Br J Ophthalmol. 1996; 80: 556-560
        • Udell IJ
        • Gleich GJ
        • Allansmith MR
        • Ackerman MR
        • Abelson MB
        Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears.
        Am J Ophthalmol. 1981; 92: 824-828
        • Akman A
        • Irkec M
        • Orhan M
        Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.
        Eye. 1998; 12: 291-295
        • Lambiase A
        • Bonini S
        • Micera A
        • Rama P
        • Bonini S
        • Aloe L
        Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases.
        Invest Ophthalmol Vis Sci. 1998; 39: 1272-1275
        • Trocmé SD
        • Kephart GM
        • Allansmith MR
        • Bourne WM
        • Gleich GJ.
        Conjunctival deposition of eosinophil granule major basic protein in vernal conjunctivitis and contact lens-associated conjunctivitis.
        Am J Ophthalmol. 1989; 108: 57-63
        • Trocmé SD
        • Gleich GJ
        • Zieske JD.
        Eosinophil granule major basic protein inhibits corneal epithelial wound healing in vitro.
        Invest Ophthalmol Vis Sci. 1991; 32 ([abstract]): 1161
        • Trocmé SD
        • Kephart GM
        • Bourne WM
        • Buckley RJ
        • Gleich GJ.
        Eosinophil major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis.
        Am J Ophthalmol. 1993; 115: 640-643
        • Hallberg CK
        • Brysk MM
        • Tyring SK
        • Gleich GJ
        • Trocmé SD.
        Toxic effects of eosinophil cationic protein on cultured human corneal epithelium.
        Invest Ophthalmol Vis Sci. 1994; ([abstract]) (poster 1943): 35
        • Trocmé SD
        • Gleich GJ
        • Kephart GM
        • Zieske JD.
        Eosinophil granule major basic protein inhibition of corneal epithelial wound healing.
        Invest Ophthalmol Vis Sci. 1994; 35: 3051-3056
        • Fukagawa K
        • Nakajima T
        • Saito H
        • Tsubota K
        • Shimmura S
        • Natori M
        • et al.
        IL-4 induces eotaxin production in corneal keratocytes but not in epithelial cells.
        Arch Allergy Immunol. 2000; 12: 144-150
        • Leonardi A
        • Borghesan F
        • Faggian D
        • Depaoli M
        • Secchi AG
        • Plebani M
        Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases.
        Am J Ophthalmol. 2000; 129: 151-158
        • Leonardi A
        • Borghesan F
        • Avarello A
        • Plebani M
        • Secchi AG
        Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.
        Br J Ophthalmol. 1997; 81: 23-26
        • Donshik PC
        • Ehlers WH
        The contact lens patient and the ocular allergies.
        Int Ophthalmol Clin. 1991; 31: 138-145
        • Srinivasan BD
        • Jakobiec FA
        • Iwamoto T
        • DeVoe AG
        Giant papillary conjunctivitis with ocular prostheses.
        Arch Ophthalmol. 1979; 97: 892-895
        • Sugar A
        • Meyer RF
        Giant papillary conjunctivitis after keratoplasty.
        Am J Ophthalmol. 1981; 92: 368-371
        • Robin JB
        • Regis-Pacheco LF
        • Mat WN
        • Schanzlin DJ
        • Smith RE
        Giant papillary conjunctivitis associated with extruded scleral buckle.
        Arch Ophthalmol. 1987; 105: 619
        • Carlson AN
        • Wilhelmus KR
        Giant papillary conjunctivitis associated with cyanoacrylate glue.
        Am J Ophthalmol. 1987; 104: 437-438
        • Heidemann DG
        • Dunn SP
        • Siegal MJ
        Unusual causes of giant papillary conjunctivitis.
        Cornea. 1993; 12: 78-80
        • Dunn JP
        • Weissman BA
        • Mondino BJ
        • Arnold AC
        Giant papillary conjunctivitis associated with elevated corneal deposits.
        Cornea. 1990; 9: 357-358
        • Versura P
        • Maltarello MC
        • Caramazza R
        • Laschi R
        Immunocytochemical analysis of contact lens surface deposits in transmission electron microscopy.
        Curr Eye Res. 1988; 7: 277-286
        • Tripathi PC
        • Tripathi RC
        Analysis of glycoprotein deposits on disposable contact lenses.
        Invest Ophthalmol Vis Sci. 1992; 33: 121-125
        • Henriquez AS
        • Allansmith MR
        Russell bodies in contact-lens-associated giant papillary conjunctivitis.
        Arch Ophthalmol. 1979; 97: 473-478
        • Elgebaly SA
        • Donshik PC
        • Rahhal F
        • Williams W
        Neutrophil chemotactic factors in tears of giant papillary conjunctivitis patients.
        Invest Ophthalmol Vis Sci. 1991; 32: 208-213
        • Allansmith MR
        • Ross RN
        Giant papillary conjunctivitis.
        Int Ophthalmol Clin. 1988; 28: 309-316
        • Irkeç M
        • Orhan M.
        Effect of extended wear disposable contact lenses on tear LTC4 in giant papillary conjunctivitis.
        Ocul Immunol Inflamm. 1995; 3: 107-111
        • Irkec MT
        • Orhan M
        • Erdener E
        Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers.
        Ocul Immunol Inflamm. 1999; 7: 35-38
        • Stenson SM.
        Lid, conjunctival, and corneal complications of contact lenses.
        in: Contact lenses. : Appleton & Lange, Norwalk (CT)1987: 215-217
        • Driebe Jr, WT
        Disposable soft contact lenses.
        Surv Ophthalmol. 1989; 34: 44-46
        • Coursaux G
        • Bloch-Michel E
        • Assin M.
        Rééquipement avec les lentilles jetables de patients porteurs de conjonctivite papillaire géante. Premiers résultats.
        Bull Soc Ophthalmol Fr. 1989; 89: 1371-1372
        • Ellis AK
        • Day JH
        • Lundie MJ
        Impact on quality of life during an allergen challenge research trial.
        Ann Allergy Asthma Immunol. 1999; 83: 33-39
        • Abelson MB
        • Paradis A
        • George MA
        • et al.
        The effects of Vasocon-A in the allergen challenge model of acute conjunctivitis.
        Arch Ophthalmol. 1990; 108: 520-524
        • Spector SL
        • Raizman MB
        Conjunctivitis medicamentosa.
        J Allergy Clin Immunol. 1994; 94: 134-136
        • Abelson MB
        • Udell IJ
        H2 receptors in the human ocular surface.
        Arch Ophthalmol. 1981; 99: 302-304
        • Weston JH
        • Udell IJ
        • Abelson MB
        H1 receptors in the human ocular surface [abstract].
        Invest Ophthalmol Vis Sci. 1981; 20: 32
        • Leysen JE
        • Gommeren W
        Drug receptor dissociation time, new tool for drug research: receptor binding affinity and drug receptor dissociation profiles of serotonin S2, dopamine D2, histamine H1 antagonists and opiates.
        Drug Develop Res. 1986; 8: 119-131
        • Arriaga F
        • Rombaut N
        Absence of central effects with levocabastine eyedrops.
        Allergy. 1990; 45: 552-554
        • Azevedo M
        • Castel-Branco MG
        • Oliveira JF
        • Ramos E
        • Delgado L
        • Almeida J
        Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis.
        Clin Exp Allergy. 1991; 21: 689-694
        • Smith LM
        • Southwick PC
        • DeRosia DR
        • Abelson MB
        The effects of levocabastine, a new highly potent and specific histamine H1 receptor antagonist, in the ocular allergen challenge model of allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1989; 30: 502
        • Pipkorn U
        • Bende M
        • Hender J
        • et al.
        A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis.
        Allergy. 1985; 40: 491-496
        • Pecoud A
        • Zuber P
        • Kolly M
        Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
        Int Arch Allergy Appl Immunol. 1987; 82: 541-543
        • McTavish D
        • Sorkin EM
        Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
        Drugs. 1989; 38: 778-800
        • McNeely W
        • Wiseman LR
        Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis.
        Drugs. 1998; 56: 91-114
        • Ciprandi G
        • Buscaglia S
        • Pesce G
        • Villagio B
        • Bagnasco M
        • Canonica GW
        Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge.
        J Allergy Clin Immunol. 1993; 91: 783-792
        • Friedlaender MH
        • Harris J
        • LaVallee N
        • Russell H
        • Shilstone J
        Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
        Ophthalmology. 2000; (In press)
        • Sharif NA
        • Xu S
        • Yanni JM
        Emedastine: pharmacological profile of a novel antihistamine for use in allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1995; 36: S135
        • Hyams SW
        • Bialik M
        • Neumann E
        Clinical trials of topical disodium cromoglycate in vernal keratoconjunctivitis.
        J Pediatr Ophthalmol. 1975; 12: 116-118
        • Loh R
        • Jabara H
        • Geha R
        Disodium cromoglycate inhibits S mu to the S epsilon deletional switch recombination and IgE synthesis in human B cells.
        J Exp Med. 1994; 180: 663-671
        • Kimata H
        • Yoshida A
        • Ishioha C
        • Mikawa H
        Sodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cells in vitro.
        Clin Exp Immunol. 1991; 84: 395-399
        • Sorkin EM
        • Ward A
        Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.
        Drugs. 1986; 31: 131-148
        • Johnson HG
        • VanHout CA
        • Wright JB
        Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,385E: I. Activity in rats.
        Int Arch Appl Allergy Immunol. 1978; 56: 416-423
        • Bonini S
        • Schiavone M
        • Bonini S
        • Magrini L
        • Lischetti P
        • Lambiase A
        • et al.
        Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
        Ophthalmology. 1997; 104: 849-853
        • Verstappen AA
        • Smith J
        • Rosenthal A
        A double-masked efficacy and safety evaluation of lodoxamide 0.1% ophthalmic solution versus opticrom 2%.
        A multicenter study in patients with allergic eye disorders. 1988 (Alcon Report #008:34350:1287)
        • Bloch-Michel E.
        Evaluation de l’efficacite therapeutique d’un collyre anti-allergique par test photographique.
        Rev Fr Allergol. 1990; 30: 163-165
        • Bonnet M
        • Ducournau D
        • Lumbroso P
        • Serpin G.
        L’acide N-acetyl aspartyl glutamique en collyre dans les conjunctivites de type allergique. Etude clinique comparative en double ensu.
        J Fr Ophtalmol. 1985; 8: 573-578
        • Van Bijsterveld OP
        • Aalders-Deenstra V
        Klinische erptobung von N-acetyl-aspartyl-glutaminasaure augetropfen bei subakuter und chronischer atophischer konjunctivitis.
        Klin Monatsbl Augenheilkd. 1988; 188: 625-627
        • Denis D
        • Bloch-Michel E
        • Verin P
        • Sebastiani Tazartes MA
        • Helleboid L
        • Di Giovanni A
        • et al.
        Treatment of common ocular allergic disorders: a comparison of lodoxamide and NAAGA.
        Br J Ophthalmol. 1998; 82: 1135-1138
        • Sharif NA
        • Xu SX
        • Miller ST
        • Gamache DA
        • Yanni JM
        Characterization of the ocular antiallergic and antihistaminic effects of olopatadine, a novel drug for treating ocular allergic disease.
        J Pharmacol Exp Ther. 1996; 278: 1252-1261
        • Sharif NA
        • Xu S
        • Yanni JM
        Olopatadine (AL-4943A): pharmacological profile of a novel antihistamine/antiallergic drug for use in allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1996; 37: S1027
        • Akman A
        • Irkec M
        • Orhan M
        Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.
        Eye. 1998; 12: 291-295
        • Yanni JM
        • Weimer LK
        • Sharif NA
        • Xu SX
        • Gamache DA
        • Spellman JM
        Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
        Arch Ophthalmol. 1999; 117: 643-647
        • Abelson MB
        • Spitalny L
        Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
        Am J Ophthalmol. 1998; 125: 797-804
        • Abelson MB
        Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
        Ann Allergy Asthma Immunol. 1998; 81: 211-218
        • Yanni JM
        • Miller ST
        • Gamache DA
        • et al.
        Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
        Ann Allergy Asthma Immunol. 1997; 79: 541-545
        • Tomioka H
        • Yoshida S
        • Tanaka M
        • et al.
        Inhibition of chemical mediator release from human leukocytes by a new antiasthma drug HC 20-511 (ketotifen).
        Mongr Allergy. 1979; 14: 313-317
        • Gonzalez JP
        • Brogden RN
        Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airway disease.
        Drugs. 1987; 34: 560-577
        • Stockwell A
        • Easty D
        Double blind comparative trial of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1988; 29: 229
        • Melamed J
        • Schwartz RH
        • Hirsch SR
        • Cohen SH
        Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis.
        Ann Allergy Asthma Immunol. 1994; 73: 57-66
        • Hirsch SR
        • Melamed J
        • Schwartz RH
        Efficacy of nedocromil sodium 2% ophthalmic solution in the treatment of ragweed seasonal allergic conjunctivitis [abstract].
        J Allergy Clin Immunol. 1988; 81: 173
        • Jarmoszuk I
        • Blumenthal M
        • Silvers W
        • et al.
        Nedocromil sodium 2% ophthalmic solution in the treatment of ragweed seasonal allergic conjunctivitis [abstract].
        J Allergy Clin Immunol. 1988; 81: 174
        • Leino M
        • Carlson C
        • Jaanio E
        • Koievunen T
        • Lavikkala HM
        • Riihela K
        • et al.
        A double bind group comparative study of 2% nedocromil sodium eye drops in the treatment of seasonal allergic conjunctivitis.
        Ann Allergy. 1990; 64: 398-402
        • Blumenthal M
        • Casale T
        • Dockhorn R
        • Jarmoszuk I
        • Kaiser H
        • Smith R
        • et al.
        A multicenter double-blind group comparative study of the efficacy and safety of b.i.d, nedocromil sodium 2% ophthalmic solution in the treatment of allergic conjunctivitis.
        Am J Ophthalmol. 1992; 113: 56-63
        • Leino M
        Studies comparing efficacy of nedocromil sodium eye drops with sodium cromoglycate and placebo in seasonal allergic conjunctivitis.
        Ocul Immunol Inflamm. 1993; 1: 21-23
        • van Bijsterveld OP
        • Moons L
        • Verdonck M
        • Kempeneers HP
        Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate.
        Ocul Immunol Inflamm. 1994; 2: 177-186
        • Verin P
        Treating severe eye allergy.
        Clin Exp Allergy. 1998; 23: 44-48
        • Woodward DF
        • Nieves AL
        • Friedlaender MH
        Mechanisms of action of ketorolac (AcularTM) in alleviating allergic conjunctival itching [abstract].
        J Allergy Clin Immunol. 1995; 95: 360
        • Tinkelman DG
        • Rupp G
        • Kaufman H
        • Pugely J
        • Schultz N
        Double-masked, paired comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eye drops in the treatment of seasonal allergic conjunctivitis.
        Surv Ophthalmol. 1993; 38: 133-140
        • Ballas Z
        • Blumenthal M
        • Tinkelman DG
        • Kriz R
        • Rupp G
        Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis.
        Surv Ophthalmol. 1993; 38: 141-148
        • Bishop K
        • Abelson M
        • Cheetham J
        • Harper D
        Evaluation of flurbiprofen in the treatment of antigen-induced allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1990; 31: 2394-2422
        • Tauber J
        • Raizman MB
        • Ostrov CS
        • Laibovitz RA
        • Abelson MB
        • Betts JG
        • et al.
        A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis.
        J Ocul Pharmacol Ther. 1998; 14: 137-145
        • Howes JF
        Loteprednol etabonate: a review of ophthalmic clinical studies.
        Pharmazie. 2000; 55: 178-183
        • Dell SJ
        • Shulman DG
        • Lowry GM
        • Howes J
        A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
        Am J Ophthalmol. 1997; 123: 791-797
        • Friedlaender MH
        • Howes J
        A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
        Am J Ophthalmol. 1997; 123: 455-464
        • Noon L
        • Cantar BO
        Prophylactic inoculation against hay fever.
        Lancet. 1911; 1: 1572-1573
        • Dreborg S
        • Agrell B
        • Foucard T
        • Kjellman M
        • Koivikko A
        • Nilsson S.
        A double blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarium preparation. I. Clinical results.
        Allergy. 1986; 41: 131-140
        • Alvarez-Cuesta E
        • Cuesta-Herranz J
        • Puyana-Ruiz J
        • Cuesta-Herranz C
        • Blanco-Quiros A
        Monoclonal antibody-standardized cat extract immunotherapy: risk benefit effects from double blind placebo study.
        J Allergy Clin Immunol. 1994; 93: 556-566
        • Donovan JP
        • Buckeridge DL
        • Briscoe MP
        • Clark RH
        • Day JH
        Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure.
        Ann Allergy Asthma Immunol. 1996; 77: 74-80
        • Ito Y
        • Takahashi Y
        • Fujita T
        • Fukuyama S
        Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination.
        Auris Nasus Larynx. 1997; 24: 163-170
        • Secchi AG
        • Tognon MS
        • Leonardi A
        Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.
        Am J Ophthalmol. 1990; 110: 641-645
        • BenEzra D
        • Peter J
        • Brosky M
        • Cohen E
        Cyclosporine eye drops for the treatment of severe vernal keratoconjunctivitis.
        Am J Ophthalmol. 1986; 101: 278-282
        • Bleik JH
        • Tabbara KF
        Topical cyclosporine in vernal keratoconjunctivitis.
        Ophthalmology. 1991; 98: 1679-1684
        • Whitcup SM
        • Chan CC
        • Luyo DA
        • Bo P
        • Li Q
        Topical cyclosporine inhibits mast cell mediated conjunctivitis.
        Invest Ophthalmol Vis Sci. 1996; 37: 2686-2693
        • Stellato C
        • de Paulis A
        • Ciccarelli A
        • et al.
        Anti-inflammatory effect of cyclosporin A on human skin mast cells.
        J Invest Dermatol. 1992; 98: 800-804
        • Wershil BK
        • Furuta GT
        • Lavigne JA
        • Choudhury AR
        • Wang ZS
        • Galli SJ.
        Dexamethasone or cyclosporine A suppress mast cell–leukocyte cytokine cascade.
        J Immunol. 1995; 154: 1391-1398
        • Hoang-Xuan T
        • Prisant O
        • Hannouche D
        • Robin H
        Systemic cyclosporine A in severe atopic keratoconjunctivitis.
        Ophthalmology. 1997; 104: 1300-1305
        • Sail K
        • Stevenson OD
        • Mundorf TK
        • Reis BL
        Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
        Ophthalmology. 2000; 107: 631-639
        • Tanaka H
        • Kuroda A
        • Marusawa H
        • et al.
        Physicochemical proterie of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.
        Transplant Proc. 1987; 19: 11-16
        • De Paulis A
        • Cirrillo R
        • Ciccarelli A
        • et al.
        FK-506, a potent novel inhibitor release of proinflammatory mediators from human Fc epsilon RI+ cells.
        J Immunol. 1991; 146: 2374-2844
        • Schreiber SL
        • Crabtree GR
        The mechanism of action of cyclosporin A and FK506.
        Immunol Today. 1992; 13: 136-142
        • Pleyer U
        • Lutz S
        • Jusko WJ
        • Ngyen K
        • Narawane M
        • Ruckert D
        • et al.
        Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye.
        Invest Ophthalmol Vis Sci. 1993; 34: 2737-2742
        • Takano T
        • Kobayashi C
        • Alba RM
        • Kanai A
        The immunosuppressive effects of 0.025% cyclosporine eye drops in alpha cyclodextrin on rabbit corneal allografts.
        Acta Societatis Ophthalmologica Japonicae. 1992; 96: 834-840
        • Nussenblatt RB
        • Caspi RR
        • Mahdi R
        • Chan CC
        • Roberge F
        • Lider O
        • et al.
        Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction with S-antigen.
        J Immunol. 1990; 144: 1689-1695
        • Vrabec TR
        • Gregerson DS
        • Dua HS
        • Donosal LA
        Inhibition of experimental autoimmune uveitis by oral administration of S-antigen and synthetic peptides.
        Autoimmunity. 1992; 12: 175-184
        • Dick AD
        • Cheng YF
        • McKinnon A
        • Liversidge J
        • Forrester JV
        Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis: a preliminary report of intranasal induction of tolerance with retinal antigens.
        Br J Ophthalmol. 1993; 77: 171-175
        • Dua HS
        • Donoso LA
        • Laibson PR
        Conjunctival instillation of retinal antigens induced tolerance.
        Ocul Immunol Inflamm. 1994; 2: 29-36
        • Koizumi T
        • Abe T
        • Sakuragi S
        Suppression of experimental allergic conjunctivitis in guinea pigs by oral administration of antigen.
        Ocul Immunol Inflamm. 1995; 3: 113-119
        • Pradalier A
        • Basset D
        • Claudel A
        • Couturier P
        • Wessel F
        • Galvain S
        • et al.
        Sublingualoswallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis.
        Allergy. 1999; 54: 819-828
        • Whitcup SM
        • Chan CC
        • Kozhich AT
        • Magone MT
        Blocking ICAM-1 (CD54) and LFA-1 (CD1 la) inhibits experimental allergic conjunctivitis.
        Clin Immunol. 1999; 93: 107-113
        • Keane-Myers AM
        • Miyazaki D
        • Liu G
        • Dekaris I
        • Ono S
        • Dana MR
        Prevention of allergic eye disease by treatment with IL-1 receptor antagonist.
        Invest Ophthalmol Vis Sci. 1999; 40: 3041-3046
        • Strauss EC
        • Larson KA
        • Brenneise I
        • Foster CS
        • Larsen GR
        • Lee NA
        • et al.
        Soluble P-selectin glycoprotein ligand 1 inhibits ocular inflammation in a murine model of allergy.
        Invest Ophthalmol Vis Sci. 1999; 40: 1336-1342
        • Floyd R
        • Kalpaxis J
        • Thayer T
        • Rangus K
        Double-blind comparison of HEPP (IgE pentapeptide) 0.5% ophthalmic solution and sodium cromolyn ophthalmic solution, USP 4%, in patients having allergic conjunctivitis [abstract].
        Invest Ophthalmol Vis Sci. 1988; 29: 45
        • Cohen GA
        • O’Connor RD
        • Hamburger RN.
        Safety and efficacy of human IgE pentapeptide.
        Ann Allergy. 1985; 52: 83-96
        • Casale T
        • Bernstein I
        • Busse W
        • LaForce C
        • Tinkelman D
        • Stoltz R
        • et al.
        Use of an anti-IgE humanized antibody in ragweed induced allergic rhinitis.
        J Allergy Clin Immunol. 1997; 100: 110-121